Skip to content
GERICLINICS

GeriQBank · Paper III · Q1

Frailty — Pathogenesis, Diagnosis, Prevention and Management

High YieldAsked ×215-mark essay
Topic
Frailty & Sarcopenia
Chapter
Frailty, Sarcopenia, Deconditioning & Biology of Ageing
Years asked
Not recorded in the source
Frequency
Set 2× in Paper III (2009–2025)

As set in the university paper

  • Describe the pathogenesis, diagnosis, prevention and management of frailty; and its pathophysiology, evaluation and management.

    Paper III · Geriatric Assessment, Frailty & Sarcopenia · asked ×2 · 15-mark essay · see in paper list

Answer framework

  1. Definition and concept — a pre-disability state; distinction from disability and comorbidity; prevalence; the frailty threshold; the cascade
  2. Pathogenesis — muscle power and executive function; cytokines and testosterone; heart failure, COPD, diabetes, anaemia; anorexia of ageing; sarcopenia
  3. Diagnosis — phenotype and cumulative deficit models; Fried, SOF and FRAIL scales; the hierarchy principle
  4. Management and prevention — the FRAIL algorithm; hormonal approaches; lifelong prevention
  5. Recent updates — Indian prevalence, ICFSR guidelines, SPRINTT, exercise plus protein, deprescribing, WHO ICOPE, hallmarks of ageing, Indian services

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 15-mark essay before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • Frailty is a pre-disability state of lost physiological reserve, distinct from disability (loss of function) and comorbidity (two or more diseases). A minor stressor tips a frail person into disability. By Fried's phenotype about 6.9% of older people are frail, women more often than men.
  • Vitality peaks at 20–30 years and then declines; exercise slows the decline and disease speeds it. The cascade runs healthy → frailty → disability → hospitalisation → institutionalisation → death, with recovery possible at each step.
  • Mechanisms: failure to generate muscle power and/or failure of executive function. Chronic disease acts through cytokines (TNF-α, IL-6, CRP) and falling testosterone. In heart failure, weight loss and hypocholesterolaemia best predict a poor outcome.
  • Other contributors: COPD; diabetes; anaemia (a single, reversible cause — corrected with iron, folate, B12 or erythropoietin); the anorexia of ageing (find reversible causes with MEALS-ON-WHEELS); and sarcopenia (testosterone falls 1% a year after 30, with low IGF-1 and vitamin D and raised myostatin). Progranulin is a named biomarker.
  • Diagnosis uses the phenotype model (Fried, Frailty Trait Scale, FRAIL) or the cumulative deficit model (Frailty Index, Clinical Frailty Scale), or the SOF index. Hierarchy: do not assess frailty in the severely ADL-dependent.
  • The FRAIL algorithm: Fatigue (exclude depression, sleep apnoea, hypothyroidism, anaemia, hypotension, B12 deficiency); Resistance (resistance exercise plus protein 1 g/kg/day); Aerobic and balance exercise; Illnesses (more than five — deprescribe); Loss of weight (look for treatable causes).
  • The textbook describes testosterone, SARMs and creatine, but no drug is now recommended for frailty. Prevention is lifelong: exercise, adequate protein and energy, vitamin D and B12, disease control, avoiding polypharmacy, and CGA to catch pre-frailty.
  • India: LASI found about 30% of people aged 60 and older frail and 58% pre-frail; pooled frailty in clinical settings is 42.3%.
  • ICFSR: screen everyone over 65 (FRAIL, gait speed or PRISMA-7), then offer resistance training, treat reversible causes, correct vitamin D, give protein-energy supplements where indicated and review medicines. SPRINTT reduced mobility disability; multicomponent exercise plus protein (1.0–1.5 g/kg/day) ranks best; deprescribing is an intervention in its own right.
  • WHO ICOPE (2nd edition, 2025) reframes frailty as intrinsic capacity across six domains. Indian supports include NPHCE clinics, the Ayushman Vay Vandana Card (aged 70 and above), Rashtriya Vayoshri Yojana and Elder Line 14567.

Condensed by GeriClinics from the detailed answer below, with no new facts added.

Geriatrics

Q1. Frailty — Pathogenesis, Diagnosis, Prevention and Management RECURS 15–20 High-Yield Points (Textbook)

A. Definition and Concept

1.

Frailty is the condition in which a person loses the ability to carry out important, practised social activities of daily living when exposed to psychological or stressful conditions.

2.

Frailty is a state of pre-disability and must be distinguished from disability and from comorbidity; it is now recognised as a public health priority.

3.

By Fried's phenotype about 6.9% of the older population are frail; women are more often frail than men of the same age.

4.

Vitality peaks between 20 and 30 years, then declines gradually; the decline is slowed by exercise and accelerated by disease, but everyone eventually crosses the frailty threshold if they live long enough.

5.

Frailty begins a cascade: Healthy → Frailty → Disability → Hospitalisation → Institutionalisation → Death (recovery is possible at each step).

B. Pathogenesis

6.

Causes are multifactorial: normal ageing physiology interacts with genes, lifestyle, environment and disease.

7.

In most people frailty results from failure to generate adequate muscle power and/or failure of executive function to use the available capacity appropriately.

8.

Chronic disease causes frailty mainly through excess cytokines (reduce muscle mass, food intake and cognition) and through a fall in testosterone.

9.

Congestive heart failure: fall in VO max; left-sided failure causes gut wall oedema → bacterial translocation → 2 endotoxin → TNF-α → anorexia, muscle loss, weight loss, hypoalbuminaemia and hypocholesterolaemia. Weight loss and hypocholesterolaemia are the best predictors of poor outcome.

10.

Angiotensin II activation cleaves actomyosin with clearance by the ubiquitin–proteasome system; ACE inhibitors reverse weight loss and frailty in some patients with CHF.

11.

COPD: loss of endurance, poor intake, raised resting metabolic rate, low testosterone and high cytokines. Diabetes: low testosterone, high angiotensin II, high cytokines, neuropathy, sarcopenia, poor executive function and accelerated atherosclerosis — mortality is increased in frail diabetics.

12.

Anaemia causes reduced endurance, weakness, orthostasis, falls, disability and death; erythropoietin or darbepoetin-α can reverse this — an example of single-cause reversible frailty.

13.

Anorexia of ageing: social isolation and low mood, reduced smell and raised taste threshold, reduced gastric compliance and adaptive relaxation causing early satiety, excess cholecystokinin, and high cytokines. In men falling testosterone raises leptin and worsens anorexia.

14.

Reversible causes of weight loss are remembered by the MEALS-ON-WHEELS mnemonic (Medications, Emotional, Alcohol/abuse, Late-life paranoia, Swallowing, Oral, Nosocomial infection, Wandering/dementia, Hyperthyroidism– hypercalcaemia–hypoadrenalism, Enteral problems, Eating problems, Low-salt/low-cholesterol diets, Stones).

15.

Sarcopenia is the core biological substrate, driven by falling testosterone (1% per year after age 30), low IGF-1, low vitamin D, raised myostatin, and raised TNF-α, IL-6 and CRP. Progranulin is described as a biomarker of frailty.

C. Diagnosis

16.

Two conceptual models: the phenotype model (Fried's criteria, Frailty Trait Scale, FRAIL scale) and the cumulative deficit model (Frailty Index, Clinical Frailty Scale).

17.

Three commonly compared scales are the Cardiovascular Health Study (Fried), the Study of Osteoporotic Fractures (SOF) index, and the FRAIL scale of the International Association of Nutrition and Aging.

18.

Principle of hierarchy: if a patient is severely ADL-dependent it is not worthwhile assessing frailty; if a patient is robust or pre-frail it is not worthwhile assessing basic ADLs.

D. Management and Prevention

19.

Management follows the FRAIL screen algorithm (Morley): Fatigue – exclude depression, sleep apnoea, hypothyroidism, anaemia, hypotension and vitamin B12 deficiency; Resistance – treat sarcopenia with resistance exercise plus protein 1 g/kg/day; Aerobic – aerobic and balance exercise; Illnesses – if more than five, consider deprescribing; Loss of weight – look for treatable causes (MEALS-ON-WHEELS).

20.

Hormonal approaches described: testosterone replacement increases muscle mass, strength and power even in non-hypogonadal men; selective androgen receptor molecules (SARMs) — steroidal (nandrolone, oxymetholone, oxandrolone) and non-steroidal (2-quinoline, coumarin, phthalimide, bicalutamide, acetothiolutamide); creatine with exercise may improve muscle performance.

21.

Prevention is lifelong: regular exercise keeps the life-slope above the frailty threshold, along with adequate protein and energy intake, correction of vitamin D and B12 deficiency, tight control of chronic disease, avoidance of polypharmacy, and comprehensive geriatric assessment to detect pre-frailty early.

Extra Points to Remember (Recurring Topic)

Frailty vs disability vs comorbidity (Fried 2004): frailty = loss of physiological reserve; disability = loss of function; comorbidity = two or more diseases. They overlap but are not the same — a favourite examiner question. The stressor is the key concept: a frail person is precipitated into disability by a minor event (urinary infection, a new drug, a short admission) that a robust person would tolerate.

Frailty can be single-cause and fully reversible — anaemia corrected with iron, folate, vitamin B12 or erythropoietin is the classic example quoted in Pathy.

Draw the frailty threshold graph (VO max / cardiac output / balance / muscle strength against age, with an 2 "exercise" line above and a "disease" line below the threshold) — earns marks quickly. Remember both mnemonics: FRAIL (screening and management) and MEALS-ON-WHEELS (weight loss).

Latest Updates (2023–Present)

Indian burden is far higher than the textbook figure. Analysis of LASI wave-1 published in the Indian Journal of Medical Research (2024) found about 30% of Indians aged 60 and above were frail and 58% pre-frail; rural 31% versus urban 25.6%; women 32.2% versus men 27.4%. A 2024 meta-analysis of Indian healthcare settings (J Family Med Prim Care) reported pooled frailty of 42.3% and pre-frailty of 39.8% in clinic and hospital populations. ICFSR International Clinical Practice Guidelines remain the operative standard: screen all adults over 65 with a validated tool (FRAIL, gait speed or PRISMA-7), then offer progressive resistance training, address reversible causes, correct vitamin D deficiency, provide protein-energy supplementation where indicated, and review medications. No drug is approved for frailty.

SPRINTT trial (Bernabei et al.) showed that a multicomponent physical activity plus nutrition programme reduced incident mobility disability in community-dwelling frail and sarcopenic older adults with SPPB 3–9 — the strongest randomised evidence to date.

Network meta-analyses (2024–2026) consistently place multicomponent exercise (resistance + aerobic + balance, with or without a cognitive task) combined with protein supplementation at the top of the ranking for reversing frailty; protein target has moved to 1.0–1.5 g/kg/day.

The Japanese Nutritional Management Guidelines for Sarcopenia and Frailty (2025) recommend energy as well as protein supplementation, noting that effects in frail and sarcopenic elders are at least as large as in healthy elders. Deprescribing is now formally an anti-frailty intervention; anticholinergics, psychotropics and inappropriately continued statins are specifically implicated in worsening frailty status.

WHO ICOPE (2nd edition, 2025) shifts the operational frame from a single frailty syndrome to intrinsic capacity across six domains (locomotion, vitality, cognition, psychological, vision, hearing), which is the model being adopted for primary care screening.

The 2023 update of the Hallmarks of Ageing (López-Otín, Cell) formally added chronic inflammation and dysbiosis, giving biological legitimacy to the inflammaging basis of frailty.

India-specific service context: NPHCE geriatric clinics and Regional Geriatric Centres, the Ayushman Vay Vandana Card (free cover of Rs 5 lakh for all citizens aged 70 and above, irrespective of income), Rashtriya Vayoshri Yojana for assistive devices, and Elder Line 14567 for social support — all relevant to a frailty care plan in an Indian answer.

Current Practice Update

Issue Textbook (Pathy 6e) Current Evidence (2023–present)

Prevalence About 6.9% of older people are frail Highly population-dependent; India ~30% frail, 58% pre-frail (LASI); up to 42% in Indian clinical settings Drug therapy Considerable emphasis on testosterone, SARMs, No pharmacological agent is recommended creatine, ACE inhibitors for frailty; testosterone is not an anti-frailty indication; exercise and nutrition are first-line Protein target 1 g/kg/day 1.0–1.5 g/kg/day, higher in acute illness, with leucine-enriched supplements where intake is poor Exercise prescription Resistance plus aerobic and balance exercise Multicomponent programme (resistance + power + balance + aerobic, ideally with a cognitive/dual task) for 3–5 months, ranked superior to any single modality Conceptual frame Frailty as a discrete pre-disability syndrome Moving to intrinsic capacity (WHO ICOPE 2nd edition) and to a frailty–sarcopenia continuum Medication review Deprescribe if more than five illnesses Deprescribing is a core, evidence-supported intervention in its own right, independent of illness count Exam One-Liners Frailty = pre-disability; disability = established loss of function.

Fried phenotype prevalence in Pathy = 6.9%; in India (LASI) = ~30%.

Best predictors of poor outcome in CHF-related frailty = weight loss and hypocholesterolaemia. Management mnemonic = FRAIL; weight-loss mnemonic = MEALS-ON-WHEELS.

Only interventions with consistent benefit = multicomponent exercise + protein + deprescribing + CGA. Biomarker named in Pathy = progranulin; inflammatory triad = TNF-α, IL-6, CRP.

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page